MountainView Hospital opens day hospital for blood cancer patients in Nevada
MountainView Hospital’s Sarah Cannon Transplant & Cellular Therapy Program today opened a Day Hospital to serve patients with blood cancer.
The 12,000-square-foot Day Hospital, which opened June 25, 2025, provides transfusions, procedures and eventually transplants, in an outpatient setting at the MountainView Hospital campus. The facility will officially open to patients on June 30.
“The opening of our Day Hospital marks a significant milestone in how we care for patients with blood cancers,” said Dr. Carolyn Mulroney, medical director of the Sarah Cannon Transplant & Cellular Therapy Program at MountainView Hospital. “By providing advanced therapies in an outpatient setting, we’re able to deliver high-quality, specialized care while reducing the burden of hospitalization for our immunocompromised patients.”
The $3 million Day Hospital has six exam rooms, six infusion bays, seven treatment rooms and one procedure room. Eventually, transplants currently done in the hospital with a long patient stay, will be done in an outpatient setting, when clinically appropriate.
“We are proud to expand our cancer care services with the launch of the Day Hospital, a first-of-its-kind facility in Nevada,” said MountainView Hospital chief executive officer Hiral Patel. “This significant investment reflects our continued commitment to bringing cutting-edge, compassionate care closer to home for patients and families facing a cancer diagnosis.”
Since opening the Sarah Cannon Transplant & Cellular Therapy Program at MountainView Hospital in 2021, more than 79 autologous transplants (also known as bone marrow transplants) have taken place. Prior to the 2021 opening of this program at MountainView Hospital, 100 percent of adult patients seeking transplants and cellular therapies had to leave the state for care.
MountainView is also the first hospital in Nevada to recently conduct two additional unique therapies aimed at treating cancer patients – the CAR T-Cell therapy – a novel immunotherapy that programs a patient’s immune system to recognize and fight cancer – and, an allogeneic stem cell transplant that involves transferring stem cells from a donor to the patient, giving the patient a new immune system to prevent recurrence of the cancer.
The Sarah Cannon Transplant & Cellular Therapy Program at MountainView Hospital is part of the Sarah Cannon Transplant & Cellular Therapy Network, offering patients convenient, community-based access to complex blood cancer care including acute leukemia, blood and marrow transplantation, clinical trials and innovative therapies. The Network treats approximately 1,600 transplant and cellular therapy patients annually across its nine FACT/JACIE accredited programs in the United States and United Kingdom.
Patients and physicians who want to learn more about MountainView’s program can call (702) 962-2106.